EFA IFA (9.09%), has received the right to grant permission from the Innovation Authority for the R&D project for a mobile blood test device Post published:06/05/2020
CARDIACSENSE Cardiacsense (6.34%) – Positive Clinical Trial Clinical Trial Detection for Cardiac Disorders Post published:04/05/2020
CARDIACSENSE Cardiacsense (about 6.34%), signed an exclusive distribution agreement for distributing medical watches in Australia and New Zealand Post published:26/04/2020
pdf1 Subsidiary (approximately 6.34%), in an exclusive distribution agreement in South Africa for the sale of medical watches for the detection of cardiac arrhythmias Post published:23/04/2020
pdf1 Memorandum of Understanding (7.97%) CD’X will provide exclusive marketing and diagnostic testing for prostate cancer diagnosis Post published:12/04/2020
pdf1 A meeting convened for 6.4.20 is adjourned for 26.4.20 discussion with shareholders of a company Post published:06/04/2020
pdf1 Merhavia has signed an agreement to cancel an option to buy Liventhal shares Post published:31/03/2020
